Loading clinical trials...

The Therapeutic Effects of Dextrose Injection for Myofascial Pain Syndrome | Clinical Trials | Clareo Health

RECRUITINGNA

The Therapeutic Effects of Dextrose Injection for Myofascial Pain Syndrome

NCT05429827•National Cheng-Kung University Hospital

Summary

Patients with an myofascial trigger point (MTrP) in their upper trapezius will be divided into three groups: Group A receiving MTrP injection with normal saline (control group), Group B with hypo-osmolar dextrose (5% dextrose), and Group C with hyper-osmolar dextrose (15% dextrose). Clinical outcomes and morphological changes will be measured before the injection, one hour after, one week after, two weeks after, and one month after the injection to delineate the therapeutic effects of dextrose injection for an MTrP.

Detailed Description

This experiment is designed to evaluate the therapeutic effects of dextrose injection on an myofascial trigger point (MTrP). Patients with an MTrP in their upper trapezius will be recruited and be divided into three groups: Group A receiving MTrP injection with normal saline (control group), Group B with hypo-osmolar dextrose (5% dextrose), and Group C with hyper-osmolar dextrose (15% dextrose). Clinical outcomes (visual analog scale, pressure pain threshold, range of motion, neck disability index) will be measured before the injection, one hour after, one week after, two weeks after, and one month after the injection. Morphological changes of an MTrP before, and after the injection will also be evaluated by sonography. Through this study, the definite therapeutic effects, and the better osmolality of dextrose injection for the treatment of an MTrP will be delineated.

Eligibility

Age

20 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1). Patients should be 20 years of age or older;
•2). They are able to communicate freely;
•3). Patients have the diagnosis of myofascial pain syndrome (MPS) with a definite myofascial trigger point (MTrP) in the neck base and upper back regions (the upper trapezius muscle). The MTrP is identiﬁed based on the following criteria, as recommended by Simons \[Simons et al., 1999\]:
•* (a). a localized tender spot in a palpable taut band of muscle ﬁbers,
•* (b). recognized pain (as the usual clinical complaint) when the tender spot is compressed,
•* (c). characteristic and consistent referred pain.
•4). Symptoms of MPS should be more than 3 weeks.

Exclusion Criteria

•(1). acute or serious medical problems;
•(2). cognitive impairment or psychiatric disorder;
•(3). coagulopathy or any other bleeding disorder;
•(4). taking medication of anticoagulation or antithrombolytics;
•(5). sensory deficiency over the body part where MTrPs located;
•(6). serum hepatitis B or acquired immunodeﬁciency syndrome;
•(7). malignancy;
•(8). pregnant or likely to be pregnant.
•(9). diabetes mellitus

Locations (1)

Department of physical Medicine and Rehabilitation, National Cheng Kung University Hospital

Tainan, Taiwan

Key Dates

Start Date

November 18, 2022

Primary Completion Date

December 20, 2025

Completion Date

December 31, 2025

Last Updated

January 1, 2025

Enrollment

ESTIMATED participants

Conditions

Myofascial Trigger Point Pain

Interventions

normal saline

OTHER

Dextrose 5% in water

DRUG

Dextrose 15% in water

DRUG

Contacts

Ta-Shen Kuan, M.D., M.S.

CONTACT

886-6-2353535 kuan@mail.ncku.edu.tw

Yao-Hong Guo, M.D., M.S.

CONTACT

886-6-2353535 n511478@mail.hosp.ncku.edu.tw

Myofascial Release Technique in Women With Primary Dysmenorrhea

NCT06492148

Dysmenorrhea PrimaryCentral Sensitisation+3 more

View study

WITHDRAWNPHASE4

Trigger Point Injections Versus Lidocaine Patch for Myofascial Pain in the Emergency Department

NCT05151510

Myofascial Trigger Point PainMyofacial Pain

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 1, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Therapeutic Effects of Dextrose Injection for Myofascial Pain Syndrome

Inclusion Criteria

Exclusion Criteria

Myofascial Release Technique in Women With Primary Dysmenorrhea

Trigger Point Injections Versus Lidocaine Patch for Myofascial Pain in the Emergency Department

Integrated Neuromuscular Inhibition Technique and Myofascial Release on Cervical Range of Motion and Dysfunction

Trigger Point Treatment in Chronic Pelvic Pain

Myofascial Points Treatment With Focused Extracorporeal Shock Waves (ESW)

Comparison of Dry Needling and Dry Cupping in Positional Fault of Pelvis